137 related articles for article (PubMed ID: 30070032)
1. Safety and efficacy of zotarolimus-eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE-DIABETES CHINA Study.
Zhu Z; Wu Y; Shen Z; Xu Y; Li Y; Wang Y; Su X; Li B; Jiang T; Jiang J; Wang L; He S; Li X; Li H; Liu Y; Zhou Y; Tang Q; Chen Y; Fang W; Jiang L; Lu C; Guo J; Zhang J; Chen S; Xia Y; Zheng H; Wang B; Zhang D; Feng L; Tang L; Xu P; Liu X; Zhang R;
J Diabetes; 2019 Mar; 11(3):204-213. PubMed ID: 30070032
[TBL] [Abstract][Full Text] [Related]
2. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
4. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
5. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
Silber S; Serruys PW; Leon MB; Meredith IT; Windecker S; Neumann FJ; Belardi J; Widimsky P; Massaro J; Novack V; Yeung AC; Saito S; Mauri L
JACC Cardiovasc Interv; 2013 Apr; 6(4):357-68. PubMed ID: 23523454
[TBL] [Abstract][Full Text] [Related]
8. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
[TBL] [Abstract][Full Text] [Related]
9. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
10. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
[TBL] [Abstract][Full Text] [Related]
11. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
12. First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.
Price MJ; Saito S; Shlofmitz RA; Spriggs DJ; Attubato M; McLaurin B; Popma Almonacid A; Brar S; Liu M; Moe E; Mehran R
JACC Cardiovasc Interv; 2017 Jul; 10(14):1381-1388. PubMed ID: 28728650
[TBL] [Abstract][Full Text] [Related]
13. Gender differences in patients treated with the zotarolimus-eluting stent at a tertiary medical center.
Shammas NW; Shammas GA; Lemke J; Miller S; Meriner S
J Invasive Cardiol; 2012 Jun; 24(6):256-60. PubMed ID: 22684377
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
Tandjung K; Sen H; Lam MK; Basalus MWZ; Louwerenburg JHW; Stoel MG; van Houwelingen KG; de Man FHAF; Linssen GCM; Saïd SAM; Nienhuis MB; Löwik MM; Verhorst PMJ; van der Palen J; von Birgelen C
J Am Coll Cardiol; 2013 Jun; 61(24):2406-2416. PubMed ID: 23602769
[TBL] [Abstract][Full Text] [Related]
15. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
[TBL] [Abstract][Full Text] [Related]
16. Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.
Sen H; Lam MK; Tandjung K; Löwik MM; Stoel MG; de Man FH; Louwerenburg JH; van Houwelingen GK; Linssen GC; Doggen CJ; Basalus MW; von Birgelen C
Catheter Cardiovasc Interv; 2015 Jan; 85(1):74-81. PubMed ID: 24585502
[TBL] [Abstract][Full Text] [Related]
17. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
18. Clinical and angiographic evaluation of the resolute zotarolimus-eluting coronary stent in Japanese patients – long-term outcome in the RESOLUTE Japan and RESOLUTE Japan small vessel study.
Saito S; Maehara A; Vlachojannis GJ; Parise H; Mehran R;
Circ J; 2015; 79(1):96-103. PubMed ID: 25428602
[TBL] [Abstract][Full Text] [Related]
19. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.
Meredith IT; Worthley S; Whitbourn R; Walters DL; McClean D; Horrigan M; Popma JJ; Cutlip DE; DePaoli A; Negoita M; Fitzgerald PJ;
JACC Cardiovasc Interv; 2009 Oct; 2(10):977-85. PubMed ID: 19850258
[TBL] [Abstract][Full Text] [Related]
20. Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial.
van Houwelingen KG; Lam MK; Löwik MM; Danse PW; Tjon Joe Gin RM; Jessurun GA; Anthonio RL; Sen H; Linssen GCM; IJzerman MJ; Doggen CJM; von Birgelen C
Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1152-1159. PubMed ID: 27595181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]